Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | DRD3 | P35462 | 5/20 | 0.36 |
| ▸ | DRD2 | P14416 | 4/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL6117488 | 0.98 | ALDH1A1 (0.49) | ALDH1A1MAPK1MAPTDRD3DRD2 | |
| SCHEMBL3802844 | 0.90 | ALDH1A1 (0.56) | ALDH1A1MAPK1MAPTDRD3DRD2 | |
| SCHEMBL13125933 | 0.89 | ALDH1A1 (0.54) | ALDH1A1MAPK1MAPTDRD3DRD2 | |
| SCHEMBL13125920 | 0.82 | ALDH1A1 (0.45) | ALDH1A1MAPK1MAPTDRD3DRD2 | |
| SCHEMBL28895600 | 0.81 | ALDH1A1 (0.51) | ALDH1A1MAPK1MAPTDRD3DRD2 | |
| SCHEMBL8278310 | 0.79 | ALDH1A1 (0.36) | ALDH1A1MAPTPOLBKDM4EMEN1 | |
| Bromide SCHEMBL6118973 | 0.78 | KDM4E (0.35) | ALDH1A1MAPTPOLBKDM4EMEN1 | |
| SCHEMBL8073165 | 0.76 | KDM4E (0.33) | ALDH1A1MAPTPOLBKDM4EMEN1 | |
| SCHEMBL7478299 | 0.73 | ALDH1A1 (0.34) | ALDH1A1MAPTPOLBKDM4EMEN1 | |
| SCHEMBL1052638 | 0.71 | LMNA (0.42) | ALDH1A1MAPTPOLBKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111298127-A | Composition comprising histamine release-promoting substance and inhibitory compound, and oral solid preparation containing the same | 黄泳华 | 2020-06-19 | — | — | CN | disclosed |
| US-8389736-B2 | Compounds having activity in correcting mutant-CFTR processing and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389736-B2 | Compounds having activity in correcting mutant-CFTR processing and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-03-05 | — | — | US | disclosed |
| US-20120129811-A1 | TRICYCLIC INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-05-24 | — | — | US | disclosed |
| US-20120129811-A1 | TRICYCLIC INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-05-24 | — | — | US | disclosed |
| WO-2012068211-A1 | TRICYCLIC INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-24 | — | — | WO | disclosed |
| WO-2012068211-A1 | TRICYCLIC INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-24 | — | — | WO | disclosed |
| US-20100273839-A1 | Compounds Having Activity in Correcting Mutant-CFTR Processing and Uses Thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2010-10-28 | — | — | US | disclosed |
| US-20100273839-A1 | Compounds Having Activity in Correcting Mutant-CFTR Processing and Uses Thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2010-10-28 | — | — | US | disclosed |
| WO-2009051909-A1 | COMPOUNDS HAVING ACTIVITY IN CORRECTING MUTANT-CFTR CELLULAR PROCESSING AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-04-23 | — | — | WO | disclosed |
| EP-1878731-B1 | Process for producing pramipexole | HELM AG (DE) | 2008-08-20 | — | — | EP | disclosed |
| EP-1878731-A1 | Process for producing pramipexole | Helm AG (DE) | 2008-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273839-A1 | Compounds Having Activity in Correcting Mutant-CFTR Processing and Uses Thereof | CFTR, ABCC5, ABCB11 | ALDH1A1 3083/4885MAPK1 4432/4885MAPT 4818/4885 |
| US-20120129811-A1 | TRICYCLIC INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION | MMP1, MMP3, MMP13 | ALDH1A1 1053/4885MAPK1 1644/4885MAPT 4816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.